2020
DOI: 10.1515/cclm-2020-0381
|View full text |Cite
|
Sign up to set email alerts
|

Proenkephalin as a new biomarker for pediatric acute kidney injury – reference values and performance in children under one year of age

Abstract: AbstractObjectivesAcute kidney injury (AKI) is common in critically ill children, but current biomarkers are suboptimal. Proenkephalin A 119–159 (PENK) is a promising new biomarker for AKI in adults, but pediatric data is lacking. We determined PENK reference intervals for healthy children, crucial for clinical implementation, and explored concentrations in critically ill infants aged under 1 year.Meth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 51 publications
0
2
0
Order By: Relevance
“…Urinary levels of kidney injury molecule-1 (KIM-1), liver-type fatty acid-binding protein (L-FABP), and the more recently discovered tissue inhibitor of metalloproteinases-2 (TIMP-2), insulinlike growth factor-binding protein 7 (IGFP7), and proenkephalin (PENK) have shown to correlate closely with degree of kidney injury in adult-intensive care patients and are available as screening panels [59]. However, for most of these novel markers of kidney function, pediatric reference intervals are still lacking or only recently being defined [60]. To date, routine use of these novel biomarkers is not (yet) implemented in many hospitals.…”
Section: Discussionmentioning
confidence: 99%
“…Urinary levels of kidney injury molecule-1 (KIM-1), liver-type fatty acid-binding protein (L-FABP), and the more recently discovered tissue inhibitor of metalloproteinases-2 (TIMP-2), insulinlike growth factor-binding protein 7 (IGFP7), and proenkephalin (PENK) have shown to correlate closely with degree of kidney injury in adult-intensive care patients and are available as screening panels [59]. However, for most of these novel markers of kidney function, pediatric reference intervals are still lacking or only recently being defined [60]. To date, routine use of these novel biomarkers is not (yet) implemented in many hospitals.…”
Section: Discussionmentioning
confidence: 99%
“…Establishment of penKid reference value in healthy infants; discrimination between AKI and non-AKI children (KDIGO) (21). PenKid levels in neonates and children correlate well with iohexol GFR measurements; discriminates between AKI and non-AKI (43).…”
Section: Neonates and Childrenmentioning
confidence: 99%